在MYC相关的DLBCL中进行了lenalidomide和剂量调整的EPOCH-R的多中心1/2期试验
Kirk E Cahill1, James K Godfrey2, Chadi Nabhan3
1Loyola University Medical Center, Maywood, Illinois, United States.
Blood advances
|July 28, 2025
概括
列纳利多米德与剂量调整的EPOCH-R化疗相结合,在双击淋巴瘤 (DHL) 和双表达性淋巴瘤 (DEL) 的患者中显示出高反应和生存率. 这种组合在1/2阶段的研究中实现了初级无进展生存目标.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 在扩散性大B细胞淋巴瘤 (DLBCL) 中同时发生的MYC和BCL2放松调节导致标准R-CHOP治疗的结果不佳.
- 剂量调整后的EPOCH-R (DA-EPOCH-R) 对双击淋巴瘤 (DHL) 有希望,但对双表达性淋巴瘤 (DEL) 和DHL的数据有限.
- 列纳利多米德 (LEN) 可能改善MYC驱动的淋巴瘤的反应.
研究的目的:
- 为了评估lenalidomide (LEN) 与剂量调整的EPOCH-R (DA-EPOCH-R) 结合在新诊断的双击淋巴瘤 (DHL) 和双表达性淋巴瘤 (DEL) 的成年人中的疗效和安全性.
主要方法:
- 由研究人员发起的,多中心的1/2期研究.
- 招募了55名新诊断的DHL或DEL的成年患者.
- 用LEN加DA-EPOCH-R治疗的患者.
主要成果:
- 总体响应率 (ORR) 为90.9%,完全响应率 (CR) 为83.6%.
- 一年和两年无进展生存率 (PFS) 分别为85.5%和78.2%.
- 2年总生存率 (OS) 为83.6%;常见的≥3级不良事件包括中性质减退 (67%) 和贫血 (67%).
结论:
- 与DA-EPOCH-R配合的LEN在DEL和DHL患者中显示出高响应率和令人鼓舞的生存结果,满足PFS主要疗效标准.
- 需要进一步的随机试验来证实LEN在这些患者群体中的特定益处.
- 组合疗法达到其主要疗效终点,表明作为治疗选择的潜力.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.6K
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
17.2K
相关概念视频
Dosage Regimen: Fixed Dose
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
